Study of NS-9 in Patients With Liver Metastases

NS Pharma

Status and phase

Completed

Phase 1

Conditions

Local Neoplasm Recurrences

Liver Neoplasms

Neoplasm Metastasis

Treatments

Drug: NS-9 [Poly I: Poly C]

Study type

Interventional

Funder types

Industry

Identifiers

NCT00094003

NS9001

Details and patient eligibility

About

This study is to investigate the safety of NS-9 and to see how well it is tolerated in patients with cancer that has metastasized (spread) to the liver from another primary tumor. NS-9 is a drug developed to go to the liver to cause cell death specifically in tumor cells. This study is also set up to determine the best dose to use.

Full description

This study requires subjects to undergo 2 treatment cycles of NS-9. Each cycle consists of once daily, 1-hour I.V. infusions of the drug for 5 days followed by a 23-day rest period. During the rest period, subjects are seen at the clinic once weekly for evaluation. Subjects having favorable or stable results after 2 cycles may continue to receive NS-9 in the extension phase of the study until the disease progresses or until they get a side effect that prevents them from continuing with therapy.

After each two cycles, if appropriate, the liver tumor will be measured by radiologic imaging to compare it to its pre-treatment size.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male and female at least 18 years of age.
Patients with liver metastases from various primary cancers for which no other curative treatment options exist.
At least one measurable lesion (by CT or MRI)
Life expectancy > 3 months
Child-bearing potential women must have a negative serum pregnancy test
ECOG performance status: 0-1
Fully recovered from any previous cancer therapy or infection (at least 4 weeks from radiation or chemotherapy, at least 3 weeks from a major surgical procedure and at least 2 weeks from an exploration/biopsy)
Discontinued from any other investigational drug for at least 30 days
Serum calcium <11 mg/dL
Absolute neutrophil count (ANC) ≥1,500/mm3, without growth factor support
Hemoglobin ≥9.0 g/dL
Platelet count ≥100,000/mm3
Serum creatinine ≤1.5 times the upper limit of normal (ULN)
Bilirubin ≤1.5 times ULN
ALT and AST ≤3 times ULN
Amylase and lipase ≤ ULN
PT and PTT < 1.5 times ULN
ECG with no acute abnormalities
Afebrile (≤37.5C or 99.5F)
Willingness and ability to comply with all study requirements

Exclusion criteria

Subject is mentally or legally incapacitated, or has significant emotional or psychiatric problems.
Concomitant primary malignant and/or non-malignant liver disease (primary liver cancer, acute or chronic hepatitis, cirrhosis, alcoholic liver disease).
History of pancreatic disease (e.g., pancreatitis, pancreatic malignancy).
New York Heart Association classification Class III or IV
Uncontrolled intercurrent illnesses including but not limited to: hypertension, seizure disorder, renal, gastrointestinal, or hematological diseases.
Clinically relevant systemic disease (other than the malignancy and malignancy-related hepatic dysfunction) making implementation of the protocol or interpretation of the study results difficult.
Pregnant or nursing, or unwilling to or will not agree to use an effective and reliable contraceptive measure.
Subject has received radiation to >25% of the total bone marrow.
Subject has a history of any other illness that would preclude study participation.
Subject has brain metastases.
Subject has allergy to egg yolk.
Subject receiving low-molecular weight heparin for treatment of a blood coagulation disorder (e.g., deep vein thrombosis, pulmonary embolism).